Can Fite Biofarma (XTAE:CANF) Total Current Assets : ₪36.53 Mil (As of Dec. 2023)

View and export this data going back to 2005. Start your Free Trial

What is Can Fite Biofarma Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Can Fite Biofarma's total current assets for the quarter that ended in Dec. 2023 was ₪36.53 Mil.

Can Fite Biofarma Total Current Assets Historical Data

The historical data trend for Can Fite Biofarma's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Can Fite Biofarma Total Current Assets Chart

Can Fite Biofarma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Current Assets

Get a 7-Day Free Trial

26.34

34.66

74.00

33.77

36.53

Can Fite Biofarma Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Current Assets	Get a 7-Day Free Trial															33.77	49.33	40.23	33.42	36.53

Can Fite Biofarma Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Can Fite Biofarma's Total Current Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	32.898	+	0	+	0	+	3.636
	=	36.53

Can Fite Biofarma's Total Current Assets for the quarter that ended in Dec. 2023 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	32.898	+	0	+	0	+	3.636
	=	36.53

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Can Fite Biofarma (XTAE:CANF) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Can Fite Biofarma's Liquidation Value for the quarter that ended in Dec. 2023 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	32.898	-	13.813	+	0.75 * 0	+	0.5 * 0
=	19.09

Can Fite Biofarma Total Current Assets Related Terms

Thank you for viewing the detailed overview of Can Fite Biofarma's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Can Fite Biofarma (XTAE:CANF) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Can Fite Biofarma Ltd (XTAE:CANF) » Definitions » Total Current Assets

Comparable Companies

Traded in Other Exchanges

CANF:USA

Address

10 Bareket Street, Kiryat Matalon, P.O. Box 7537, Petah-Tikva, ISR, 4951778

Website

http://www.canfite.com

Can Fite Biofarma Ltd is an advanced clinical stage drug development company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, liver, and inflammatory disease. The company's lead drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the most common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).